CN103127010B - 一种稳定的坎地沙坦酯片剂组合物 - Google Patents
一种稳定的坎地沙坦酯片剂组合物 Download PDFInfo
- Publication number
- CN103127010B CN103127010B CN201210084203.4A CN201210084203A CN103127010B CN 103127010 B CN103127010 B CN 103127010B CN 201210084203 A CN201210084203 A CN 201210084203A CN 103127010 B CN103127010 B CN 103127010B
- Authority
- CN
- China
- Prior art keywords
- candesartan cilexetil
- adds
- sodium carboxymethyl
- carboxymethyl cellulose
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229960004349 candesartan cilexetil Drugs 0.000 title claims abstract description 33
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 239000013078 crystal Substances 0.000 claims abstract description 21
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 16
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 16
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 13
- 229920002472 Starch Polymers 0.000 claims abstract description 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 13
- 239000008101 lactose Substances 0.000 claims abstract description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- 229950005770 hyprolose Drugs 0.000 claims description 12
- 239000007916 tablet composition Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000003754 machining Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 7
- 238000003825 pressing Methods 0.000 description 6
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 5
- -1 Candesartan ester Chemical class 0.000 description 5
- 229960000932 candesartan Drugs 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210084203.4A CN103127010B (zh) | 2012-03-19 | 2012-03-19 | 一种稳定的坎地沙坦酯片剂组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210084203.4A CN103127010B (zh) | 2012-03-19 | 2012-03-19 | 一种稳定的坎地沙坦酯片剂组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103127010A CN103127010A (zh) | 2013-06-05 |
CN103127010B true CN103127010B (zh) | 2014-09-24 |
Family
ID=48487887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210084203.4A Active CN103127010B (zh) | 2012-03-19 | 2012-03-19 | 一种稳定的坎地沙坦酯片剂组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103127010B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104688696B (zh) * | 2013-12-04 | 2017-12-19 | 长春海悦药业股份有限公司 | 一种含有坎地沙坦酯的药物组合物 |
CN104758252B (zh) * | 2014-01-03 | 2019-11-12 | 广东东阳光药业有限公司 | 坎地沙坦酯组合物 |
CN110638772A (zh) * | 2019-10-29 | 2020-01-03 | 白喜平 | 一种奥美沙坦酯片剂及其制备方法 |
CN110876726A (zh) * | 2019-11-20 | 2020-03-13 | 白喜平 | 一种坎地沙坦酯制剂及其制备方法 |
CN115671063B (zh) * | 2022-08-12 | 2023-10-13 | 迪沙药业集团有限公司 | 一种坎地沙坦酯药物组合物及其制备方法 |
CN116492336A (zh) * | 2023-04-04 | 2023-07-28 | 迪沙药业集团有限公司 | 一种坎地沙坦酯药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101590042A (zh) * | 2009-06-24 | 2009-12-02 | 迪沙药业集团有限公司 | 稳定的口服药物组合物 |
CN101623275A (zh) * | 2009-03-16 | 2010-01-13 | 江苏天一时制药有限公司 | 一种含有坎地沙坦酯的胶囊剂及其制备方法 |
CN101766600A (zh) * | 2008-12-29 | 2010-07-07 | 北京琥珀光华医药科技开发有限公司 | 一种复方坎地沙坦酯制剂及其制备方法 |
-
2012
- 2012-03-19 CN CN201210084203.4A patent/CN103127010B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101766600A (zh) * | 2008-12-29 | 2010-07-07 | 北京琥珀光华医药科技开发有限公司 | 一种复方坎地沙坦酯制剂及其制备方法 |
CN101623275A (zh) * | 2009-03-16 | 2010-01-13 | 江苏天一时制药有限公司 | 一种含有坎地沙坦酯的胶囊剂及其制备方法 |
CN101590042A (zh) * | 2009-06-24 | 2009-12-02 | 迪沙药业集团有限公司 | 稳定的口服药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN103127010A (zh) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103127010B (zh) | 一种稳定的坎地沙坦酯片剂组合物 | |
EP3981399A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
KR101628937B1 (ko) | 콜린알포세레이트를 함유하는 정제 및 그 제조방법 | |
JP6759390B2 (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
US9616027B2 (en) | Pramipexole sustained release tablet formulation and manufacturing method thereof and use thereof | |
TW201010693A (en) | Stable medicinal composition comprising tranexamic acid and ascorbic acid | |
AU2018256998A1 (en) | Pharmaceutical composition for oral administration comprising | |
CN102138911B (zh) | 一种双丙戊酸钠缓释片及其制备方法 | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
CN110420192A (zh) | 一种单硝酸异山梨酯缓释片及制备方法 | |
CN103610658B (zh) | 一种免疫调节剂缓释剂及其制备方法 | |
Patel et al. | Formulation development and process optimization of theophylline sustained release matrix tablet | |
CN107753458A (zh) | 尼莫地平片剂药物组合物和制法 | |
CN102240291A (zh) | 一种含伊马替尼的组合物及其制备方法 | |
CN102512415B (zh) | 一种硫酸氢氯吡格雷药物组合物及制备方法 | |
CN105012264A (zh) | 丙戊酸钠缓释片及其制备工艺和用途 | |
CN102846625A (zh) | 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法 | |
WO2021123192A1 (en) | Edoxaban tablets | |
CN102526748A (zh) | 含有缬沙坦、氢氯噻嗪和苯磺酸氨氯地平的口服片剂 | |
CN102657628A (zh) | 一种含辛伐他汀的药物组合物及其制备方法 | |
CN105395506A (zh) | 一种盐酸可乐定缓释片 | |
CN105030707B (zh) | 一种基于改性葡萄糖全粉末直压法制备克霉唑含片的方法 | |
CN103690503B (zh) | 一种双层片的制备方法 | |
CZ2006392A3 (cs) | Tableta s obsahem metforminu | |
CN106983728B (zh) | 普拉克索缓释片及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160822 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Shandong Disha Pharmaceutical Co.,Ltd., Disha Phamaceutical Group Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: Weihai Weitai Pharmaceutical Technology Development Co.,Ltd. |
|
CB02 | Change of applicant information |
Inventor after: Gao Yongji Inventor after: Long Lianqing Inventor after: Wang Guan Inventor after: Wang Yinfeng Inventor after: Yue Liping Inventor before: Long Lianqing Inventor before: Wang Yinfeng Inventor before: Yue Liping |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200525 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee after: Dijia Pharmaceutical Group Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Co-patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210621 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A stable candesartan axetil tablet composition Effective date of registration: 20220721 Granted publication date: 20140924 Pledgee: Bank of China Limited Weihai Branch Pledgor: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2022980010828 |